Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Buse

Showing results (131-140 of 457) with videos related to

Pageof 46
Sort By:
Clinical Drug Investigation|July 29, 2020
Comprehensive Pulmonary Safety Review of Inhaled Technosphere<sup>®</sup> Insulin in Patients with Diabetes MellitusJanet B McGill, Anne Peters, John B Buse, et al.
The American Journal of Gastroenterology|April 26, 2024
Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept StudyHans Herfarth, Millie D Long, Jonathan J Hansen, et al.
The Lancet. Diabetes & Endocrinology|February 19, 2021
Positioning newer drugs in the management of type 2 diabetesNikolaus Marx, Melanie J Davies, Peter J Grant, et al.
Advanced Materials (Deerfield Beach, Fla.)|March 8, 2017
Red Blood Cells for Glucose-Responsive Insulin DeliveryChao Wang, Yanqi Ye, Wujin Sun, et al.
Diabetes Care|January 28, 2010
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefitsDaniel J Drucker, Steven I Sherman, Fred S Gorelick, et al.
Diabetes Care|May 30, 2006
1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetesKathleen M Dungan, John B Buse, Joseph Largay, et al.
The Lancet. Diabetes & Endocrinology|November 7, 2020
Guideline recommendations and the positioning of newer drugs in type 2 diabetes careNikolaus Marx, Melanie J Davies, Peter J Grant, et al.
The Oncologist|March 18, 2020
Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic CancerRobert W Corty, Benjamin W Langworthy, Jason P Fine, et al.
Diabetes Technology & Therapeutics|May 13, 2020
Inpatient Transition to Virtual Care During COVID-19 PandemicMorgan S Jones, April L Goley, Bonnie E Alexander, et al.
American Journal of Epidemiology|September 3, 2024
A systematic approach to evaluating instrumental variable assumptions: applied example of glucose-lowering medications and risk for hospitalized heart failure in older adultsPhyo T Htoo, Jessie K Edwards, Mugdha Gokhale, et al.
Pageof 46

Showing results (131-140 of 457) with videos related to

Sort By:
Pageof 46
Clinical Drug Investigation|July 29, 2020
Comprehensive Pulmonary Safety Review of Inhaled Technosphere<sup>®</sup> Insulin in Patients with Diabetes MellitusJanet B McGill, Anne Peters, John B Buse, et al.
The American Journal of Gastroenterology|April 26, 2024
Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept StudyHans Herfarth, Millie D Long, Jonathan J Hansen, et al.
The Lancet. Diabetes & Endocrinology|February 19, 2021
Positioning newer drugs in the management of type 2 diabetesNikolaus Marx, Melanie J Davies, Peter J Grant, et al.
Advanced Materials (Deerfield Beach, Fla.)|March 8, 2017
Red Blood Cells for Glucose-Responsive Insulin DeliveryChao Wang, Yanqi Ye, Wujin Sun, et al.
Diabetes Care|January 28, 2010
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefitsDaniel J Drucker, Steven I Sherman, Fred S Gorelick, et al.
Diabetes Care|May 30, 2006
1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetesKathleen M Dungan, John B Buse, Joseph Largay, et al.
The Lancet. Diabetes & Endocrinology|November 7, 2020
Guideline recommendations and the positioning of newer drugs in type 2 diabetes careNikolaus Marx, Melanie J Davies, Peter J Grant, et al.
The Oncologist|March 18, 2020
Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic CancerRobert W Corty, Benjamin W Langworthy, Jason P Fine, et al.
Diabetes Technology & Therapeutics|May 13, 2020
Inpatient Transition to Virtual Care During COVID-19 PandemicMorgan S Jones, April L Goley, Bonnie E Alexander, et al.
American Journal of Epidemiology|September 3, 2024
A systematic approach to evaluating instrumental variable assumptions: applied example of glucose-lowering medications and risk for hospitalized heart failure in older adultsPhyo T Htoo, Jessie K Edwards, Mugdha Gokhale, et al.
Pageof 46